WASHINGTON — It’s a small update to a Food and Drug Administration policy first launched by the Obama administration, but top Trump health officials — and key congressional Republicans and drug makers — are nonetheless touting it as a central part of the Trump camp’s efforts to lower prescription drug prices.
On Tuesday, the FDA finalized guidance documents, released in draft form in mid-January 2017, making it clear that drug and device companies are allowed to share with insurers information that is not in the FDA-approved labeling. Insurers can use that information to determine how much they should pay for the drugs, FDA commissioner Scott Gottlieb said in a statement.
